These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3376191)

  • 21. [Study of hepatic drug metabolism. For a rationalization of a new molecular development].
    Le Dinh T; Christoforov B
    Therapie; 1994; 49(2):133-40. PubMed ID: 7817337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytochrome P450-mediated metabolism in the human gut wall.
    Thelen K; Dressman JB
    J Pharm Pharmacol; 2009 May; 61(5):541-58. PubMed ID: 19405992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fast regulation of cytochrome P450 activities by phosphorylation and consequences for drug metabolism and toxicity.
    Oesch-Bartlomowicz B; Oesch F
    Biol Chem; 2002 Oct; 383(10):1587-92. PubMed ID: 12452435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Drug metabolism by the cytochrome p-450 enzyme. Variability of polymorphisms and exogenous carriers].
    Kreutzkamp B
    Med Monatsschr Pharm; 2006 Feb; 29(2):48-50. PubMed ID: 16506587
    [No Abstract]   [Full Text] [Related]  

  • 25. Correlations between cytochrome P-450 and oxidative metabolism of benzo[a]pyrene and 7-ethoxycoumarin in human liver in vitro and antipyrine elimination in vivo.
    Pelkonen O; Sotaniemi E; Tokola O; Ahokas JT
    Drug Metab Dispos; 1980; 8(4):218-22. PubMed ID: 6105054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of age on the oxidative metabolism of antipyrine by uninduced microsomal fractions of rat liver.
    Van Geel CA; Van Bezooijen CF
    Mech Ageing Dev; 1990 Apr; 53(2):169-77. PubMed ID: 2342384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Main drug- and carcinogen-metabolizing enzyme systems in human non-small cell lung cancer and peritumoral tissues.
    Toussaint C; Albin N; Massaad L; Grunenwald D; Parise O; Morizet J; Gouyette A; Chabot GG
    Cancer Res; 1993 Oct; 53(19):4608-12. PubMed ID: 8402635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Elimination of caffeine and metamizol in in vivo characterization of cytochrome P-450 dependent biotransformation reactions in aged humans].
    Ortweiler W; Stein G; Simon HU; Siegert C; Splinter FK; Traeger A
    Pharmazie; 1985 Nov; 40(11):787-90. PubMed ID: 4095131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients.
    Brockmeyer NH; Gambichler T; Bader A; Kreuter A; Kurowski M; Sander P; Altmeyer P
    Eur J Med Res; 2004 Feb; 9(2):51-4. PubMed ID: 15090289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphic differences in drug metabolism and response.
    Vetticaden SJ
    Methods Find Exp Clin Pharmacol; 1988 Aug; 10(8):531-6. PubMed ID: 3067018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Monooxigenase activity in liver diseases (study based on data of antipyrine metabolism)].
    Loginov AS; Bendikov EA; Kel'nia ZhA; Petrakov AV
    Ter Arkh; 1987; 59(2):84-9. PubMed ID: 3576485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nutritional parameters that alter hepatic drug metabolism, conjugation, and toxicity.
    Bidlack WR; Brown RC; Mohan C
    Fed Proc; 1986 Feb; 45(2):142-8. PubMed ID: 3510912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
    Lynch T; Price A
    Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatic drug clearance in patients with mild cystic fibrosis.
    Kearns GL; Crom WR; Karlson KH; Mallory GB; Evans WE
    Clin Pharmacol Ther; 1996 May; 59(5):529-40. PubMed ID: 8646824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of hexobarbital and antipyrine metabolism by rifampicin treatment in the pig.
    van den Broek JM; Teunissen MW; Breimer DD
    Drug Metab Dispos; 1981; 9(6):541-4. PubMed ID: 6120813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions.
    Stringer RA; Strain-Damerell C; Nicklin P; Houston JB
    Drug Metab Dispos; 2009 May; 37(5):1025-34. PubMed ID: 19196847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes.
    Touw DJ
    Drug Metabol Drug Interact; 1997; 14(2):55-82. PubMed ID: 9893738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
    McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
    Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach.
    Schellens JH; van der Wart JH; Danhof M; van der Velde EA; Breimer DD
    Br J Clin Pharmacol; 1988 Oct; 26(4):373-84. PubMed ID: 3190987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between the metabolism of antipyrine, hexobarbital and theophylline in patients with liver disease as assessed by a 'cocktail' approach.
    Schellens JH; Janssens AR; van der Wart JH; van der Velde EA; Breimer DD
    Eur J Clin Invest; 1989 Oct; 19(5):472-9. PubMed ID: 2511024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.